No Data
No Data
Wells Fargo Maintains Immunovant(IMVT.US) With Buy Rating, Cuts Target Price to $45
Immunovant Price Target Lowered to $45 From $47 at Wells Fargo
Immunovant Is Maintained at Overweight by Wells Fargo
Immunovant Analyst Ratings
FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline With Promising Results and FDA Green Light for Pivotal Trial
Graves' Disease Pipeline Drug Research Report 2024 Featuring Viridian Therapeutics, Immunovant Sciences, Apitope International, Sling Therapeutics, and Novartis